Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR3 |
Variant | G370C |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR3 G370C lies within the juxtamembrane region of the Fgfr3 protein (PMID: 12009017). G370C confers a gain of function to the Fgfr3 protein as demonstrated by increased Fgfr3 phosphorylation, constitutive activation of the Mapk signaling pathway (PMID: 12009017), a growth advantage relative to wild-type Fgfr3 in a competition assay, and increased transformation activity in cultured cells (PMID: 34272467). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR3 mutant FGFR3 act mut FGFR3 G370C |
Transcript | NM_000142.5 |
gDNA | chr4:g.1804362G>T |
cDNA | c.1108G>T |
Protein | p.G370C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001354810.2 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_011513422.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
NM_001354809.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_011513420.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_047449822.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_006713873.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_006713872 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_047449824.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_006713873.2 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_011513420.2 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
NM_001354809.2 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
NM_000142.5 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
NM_000142 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_011513420 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_011513422 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
NM_001354810.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
NM_000142.4 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_006713873 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_011513422.2 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
XM_047449823.1 | chr4:g.1804362G>T | c.1108G>T | p.G370C | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05564416 | Phase II | Erdafitinib Atezolizumab + Erdafitinib | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | Withdrawn | 0 | |
NCT05627063 | Phase I | ABSK121 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04917809 | Phase II | Erdafitinib | A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | Recruiting | USA | 0 |